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94 The Journal of Thoracic and Cardiobjective: Combination chemotherapy is considered the first-line treatment for
ulmonary tuberculosis. Despite related morbidity, the need for surgical resections
oincides with the emergence of multidrug-resistant tuberculosis. This study pre-
ents a single-institution retrospective audit of the surgical management of 23
atients with multidrug-resistant tuberculosis.
ethods: We analyzed 23 consecutive patients undergoing anatomic pulmonary
esections for human immunodeficiency virus–negative multidrug-resistant tuber-
ulosis. Twenty were male (87%) and 3 were female (13%); their mean age was
4.4 years. We defined resistance in this cohort as failure to respond to combination
hemotherapy, including isoniazid and rifampicin, with a mean duration of admin-
stration being 90 days. Fifteen of 23 (65.3%) patients, although sputum negative,
ere considered at risk for relapse owing to extensive parenchymal disease. Eight
34.7%) of 23 patients were sputum positive at the time of operation. We performed
neumonectomy on 11 (47.8%) and lobectomy on 12 (52%) patients. All had
djuvant chemotherapy for 18 to 24 months, with follow-ups ranging from 14 to 27
onths.
esults: Stay in the intensive treatment unit was 2.9 days (range 1–17 days) and
ospital stay, 8.6 days (range 5–45 days). Four (17%) patients had prolonged air
eak, 3 (13%) required further treatment for empyema, with re-exploration for
leeding in 1 (4%). Hospital mortality was 4.3%. All patients attained sputum-
egative status postoperatively (range 1-5 months). One (4%) patient had a relapse
fter 12 months.
onclusion: Surgery should be considered as an adjunct to medical therapy when
radicating multidrug-resistant tuberculosis in affected patients. Anatomic lung
esections can be performed with acceptable morbidity and mortality. Early referral
f such patients for surgical consideration is warranted.
he incidence of tuberculosis in Egypt is 27 per 100,000 population per year.
The success of the authorities in controlling infection by adopting a policy of
directly observed treatment has reached 80%. However, the prevalence of
ewly diagnosed cases of multidrug-resistant tuberculosis (MDR-TB) is approxi-
ately 2.2%. If treatment is subtherapeutic, this estimate climbs to 7.1%.1 Surgery
or pulmonary tuberculosis was an important form of therapy until the introduction
f antibiotics in the 1960s. The benefits of appropriate chemotherapy outweighed
urgery, with a cure achieved in all patients with tuberculosis.2,3 The emergence o
trains resistant to rifampicin and isoniazid, however, as well as of such atypical
ycobacteria as Mycobacterium avium-intracellulare, has questioned the complete-ess of the benefits of medical therapy. Surgical options have once again emerged
vascular Surgery ● July 2007
a e
r
c
M
B
t
v
(
y
t
e
i
r
c
o
W
f
m
t
t
l
(
p
m
b
c
p
fl
p
(
r
t
s
n
c
l
r
c
p
n
m
r
W
s
s
w
d
l
t
T
s
c
t
v
b
p
c
p
P
A
a
s
c
a
r
t
s
r
T
A
G
B
O
P
X
M
P
P
P
P
M
M
F
Mohsen et al General Thoracic Surgery
G
TSs a necessary treatment modality.4,5 In this study, w
etrospectively analyzed the indications, surgical outcomes,
omplications, and follow-up of patients with MDR-TB.
aterials and Methods
etween 1999 and 2005, 23 patients underwent pulmonary resec-
ions at Cairo University Hospital for human immunodeficiency
irus–negative stage III MDR-TB. Twenty (87%) were male and 3
13%) were female, with a mean age of 24.4 years (range 7-48
ears).
Preoperative evaluation included history and clinical examina-
ion to address any comorbidity, particularly underlying lung dis-
ase (ie, bronchiectasis), diabetes, anemia, and hypoalbuminemia,
nvolving the performance of chest radiography, computed tomog-
aphy, and bronchoscopy to rule out the rare endobronchial tuber-
ulosis, and pulmonary function tests and echocardiograms to rule
ut pulmonary hypertension.
All patients in whom sputum conversion failed, following
orld Health Organization recommendations, started with 4 drugs
or 2 months of a directly observed treatment short course. At 4
onths of persistent sputum positivity we considered the treatment
o have failed. At this stage we tested for culture and drug sensi-
ivity with the BACTEC TB 460 assay (Becton Dickinson, Frank-
in Lakes, NJ). All patients were resistant to a median of 4 drugs
range 2 to 6 drugs), including rifampicin and isoniazid. In the
reoperative period all patients were placed on a regimen of
ultidrug therapy, with a median of 4 drugs (range 3-6 drugs),
ased on appropriate chemotherapy sensitivity profiling. Pharma-
ologic agents included pyrazinamide, ethambutol, streptomycin,
ara-aminosalicylic acid, and fluoroquinolones (floxacin, levo-
oxacin, and gatifloxacin), the latter used in 15 (65.3%) of 23
atients in this study. The regimen was given for at least 3 months
range 3-6 months).
The criteria for patient selection and indications for surgical
esections as adjunct to medical treatment were (1) drug resistance
o at least 2 drugs (isoniazid and rifampicin), (2) failure to convert
putum or a previous relapse in compliant patients, (3) sputum-
egative patients with a high probability of relapse owing to
onsiderable parenchymal destruction (cavitary lesion or destroyed
ung), (4) the availability of adequate drug efficacy to provide
apid healing of the bronchial stump, (5) the disease being suffi-
iently localized so that resection would leave an adequate cardio-
ulmonary capacity, and (6) the operation being performed after
eoadjuvant chemotherapy for at least 3 months (range 3-6
onths).5
We performed 11 pneumonectomies (10 on the left and 1 on the
ight) and 12 upper lobectomies (8 on the right and 4 on the left).
e have operated unilaterally on this series of patients, targeting
uch gross diseases as cavity and destroyed lobes, or managing
uch complications as hemoptysis or mycetoma. The operation
as performed under general anesthesia, with double-lumen en-
Abbreviations and Acronyms
MDR-TBmultidrug-resistant tuberculosisotracheal tubes used to prevent contamination of the nonoperated r
The Journal of Thoracicung through the bronchial tree. In all patients the approach was
hrough a standard muscle-sparing, posterolateral thoracotomy.
he dissection of dense adhesions in some patients was not pos-
ible and an extrapleural approach was used to avoid opening
avitary lesions and to reduce blood loss (in 7 of 11 pneumonec-
omies). The use of the Harmonic scalpel (Ethicon, Inc, Somer-
ille, NJ) also contributed to the reduction of blood loss. All
ronchial stumps were sutured and reinforced with pleural flaps or
ericardial fat pads. Warm saline was used to irrigate the pleural
avity, together with povidone-iodine. All specimens were sent for
athologic and bacteriologic evaluation.
ostoperative Care
ll patients were weaned from the ventilator immediately
fter the operation in the operating theater. We did not use
uction and depended on proper analgesia using epidural
atheters, physiotherapy, incentive spirometry, and early
mbulation (6–8 hours postoperatively).
All patients recommenced their preoperative multidrug
egimen as soon as they resumed oral intake. They were
ransferred from the high dependency unit to the thoracic
urgical ward once hemodynamically stable and after the
emoval of all chest drains. We followed a protocol of early
ABLE 1. Clinical profile of 23 patients with MDR-TB
ge (mean), y 24.4 (7–48)
ender 20 M/3 F
ody mass index 20.43 2.84
rigin, n
Egyptian 9
Yemeni 7
Sudani 4
Libyan 3
reop associated complications, n
Hemoptysis 4
Fungus ball 3
-ray findings, n (%)
Cavity 9 (39.1%)
Bronchiectasis 3 (13%)
Destroyed lung 11 (37.8%)
Bilateral lesions 4 (17.3%)
edian No. of resistant drugs 4 (3–6)
reop duration of medical treatment, mo 3–6
reop organisms identified Mycobacterium
tuberculosis
reop positive sputum, No. patients (%) 8/23 (34.7%)
reop pulmonary reserve
FVC (L) 3.15 0.75
FVC% of predicted (%) 100.6 18.9
FEV1.0 2.23 0.82
FEV1.0 % of predicted (%) 92.5 28.4
edian postop conversion time, mo 3 (1–5)
DR-TB, Multidrug-resistant tuberculosis; FVC, forced vital capacity;
EV1.0 , forced expiratory volume in 1 second.emoval of chest drains after pneumonectomy as long as
and Cardiovascular Surgery ● Volume 134, Number 1 195
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1
G
TSrainage was less than 2 mL/kg in 24 hours. No alteration in
ndividual multidrug regimens was necessary, following
eviews of specimen cultures and drug susceptibility pro-
les. The follow-up period extended from 14 to 27 months.
rugs were administered for from 18 to 24 months, except
n 1 case, in which drugs were administered for 12 months
nly.
esults
atients’ preoperative demographics and variables are
hown in Table 1. There was 1 (4.3%) perioperative d
his patient, who had undergone right pneumonectomy for
destroyed lung, had a high fever, and an empyema was
iagnosed on the fifth postoperative day. His condition was
omplicated by esophageal perforation. On the 11th post-
perative day a bronchopleural fistula developed and he
eeded mechanical ventilation. His condition continued to
eteriorate and he died on the 17th postoperative day of
ultiorgan failure.
Postoperative complications occurred in 8 (34.7%) pa-
ients. The major complication was prolonged air leakage
or more than 7 days (range 11 days to 7 months) in 4
33.3%) of 12 patients having lobectomy. The air leaks
eveloped mostly from the fissure area.
One patient had incomplete fissure and an air leak was
nevitable; then the lung failed to expand, and we re-
xplored the hemithorax 10 days later. At the operation
here was a peel hindering lung expansion and a small area
f air leakage at the fissure. The peel was dissected and the
ite of the air leak was hand sewn. Lung expansion was
chieved and the patient had an uneventful postoperative
ourse and was discharged home a week later.
We treated the other 3 conservatively. Two responded to
epeated autologous blood. One hundred fifty milliliters of
utologous blood was injected through the anterior chest
ube for 2 successive days, while clamping for 1 hour each
ime. Both patients’ leaks became minimal after the first
njection and stopped after the second. The last patient
efused any further intervention and was discharged home
ith a Heimlich valve; her air leak stopped 7 months later.
Of the survivors, 3 patients had empyema. One patient
ad a high fever and elevated white blood cell count on day
after left pneumonectomy. The bacteriologic culture from
he thin turbid fluid tapped revealed Staphylococcus aureus,
hich was sensitive to vancomycin. A wide-bore dependent
horacostomy tube was placed, and systemic as well as local
ancomycin in 2 L of warm saline was given 3 times a day
ia a central venous catheter placed in the second intercostal
pace. This was done for 5 days; repeated cultures taken
rom the drains were negative. The tube was removed on
ay 15 and the patient was discharged home.
The second patient had empyema after a right upper
obectomy. Drains were kept in place, and no organism was r
96 The Journal of Thoracic and Cardiovascular Surgery ● July.
etected on repeated cultures. Although full lung expansion
as achieved, multiple fluid levels developed and localiza-
ion occurred with a posterior pouch. When drainage was
inimal (less than 2 mL/kg in 24 hours) after 4 weeks,
e-exploration, debridement, and decortication were per-
ormed and achieved good results. The patient was dis-
harged 10 days later.
The third patient had a posterior pouch on day 9 after the
rains were removed. However, pleural aspiration revealed
hat turbid fluid and Escherichia coli had been cultured. The
ouch was cleared and the peel was dissected by video-
ssisted thoracoscopy aided by manual lung bagging. A
ependent wide-bore drain was placed and a lavage with
ntibiotics was done for 5 days. The patient was discharged
ome on day 2.
One patient underwent re-exploration after 24 hours ow-
ng to high drainage, and at operation no source of bleeding
as found and a large hematoma was evacuated.
Four patients with bilateral disease (17.3 %) were man-
ged unilaterally with upper lobectomies. Three had fungal
alls and 1 had upper lobe bronchiectasis, which was the
ource of hemoptysis (confirmed by bronchoscopy). In
hese patients the contralateral side had minimal infiltrations
hat responded to medical therapy at follow-up.
The organism identified preoperatively in all cases was
ycobacterium tuberculosis. The incidence of positive and
egative sputum at the time of the operation was 65.3%
n  15) and 34.7% (n  8), respectively. All survivors
ere culture negative after the operation, within a median of
months (range 1-5 months). One patient had a relapse after
2 months of retreatment. He discontinued the treatment
nd returned with symptoms. His culture was positive and
e lost him to follow-up.
iscussion
he emergence of MDR-TB is a global problem.6 Its rising
ncidence in developed countries, and more recently even in
eveloping countries, has been attributed to immigration,
omelessness, intravenous drug abuse, and acquired immu-
odeficiency syndrome. On the other hand, the problem in
eveloping countries is attributed to poor patient compli-
nce, illiteracy, and inadequate follow-up, thus allowing
rug resistance and the progression of the disease to oc7
t has been estimated that the cost of treating drug-sensitive
uberculosis may range from $2,000 to $15,000 per patient.
his pales in comparison with the treatment of MDR-TB,
hich may approach $200,000.4
To date there is no randomized, controlled study com-
aring the efficacy of surgical treatment plus chemotherapy
ith the efficacy of chemotherapy alone. However, the
ailure rate of medical therapy is calculated to be more than
0%, with a poor long-term survival reported.8 The cure
ate with surgical resectioning as an adjunct to medical
2007
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G
TSherapy approximates 83% to 93% in some published se-
ies.8,9 Surgical treatment reduces the bacterial burden 
esecting cavitary lesions or destroyed lobes. It may also
anage such complications of persistent infection as he-
optysis, bronchopleural fistulas, empyema, or persistent
ocalized infection in destroyed lungs or distal to a bron-
hostenosis. Our indications for surgery in patients with
DR-TB are similar to those of others,5,10-15 presuming
hat there is adequate cardiopulmonary reserve. It is impor-
ant to note that at least 3 months of treatment should be
iven before surgery, if at all feasible.4,9,16 The introduction
f fluoroquinolone antibiotics has raised hopes of improving
he current dismal prognosis for MDR-TB.9
The indications for surgery were as follows:
1. Drug resistance to at least 2 drugs, including isonai-
zid and refampicin; this was discovered after drug
susceptibility in patients who failed to convert from
sputum-positive smears to sputum-negative smears
2. Previous relapse(s) in patients with histories of tu-
berculosis and proper drug regimen
3. Sputum-negative results in patients who have a high
probability of relapse owing to such gross lung dis-
eases as bronchiectasis, cavitary lung lesions, or de-
stroyed lungs or lobes
4. The availability of a drug regimen to provide rapid
healing of the bronchial stump. This indication is
essential in patients with rare endobronchial tubercu-
losis. However, we did not encounter that in our
series. Moreover, 8 of our patients were sputum pos-
itive at operation, but still we did not experience
stump problems
5. Resectioning confined to localized disease, provided
that adequate cardiopulmonary function was left
6. An umbrella of susceptible drug regimen for at least
3 months or more could precede surgical intervention
When the probability of the negative bacteriologic conver-
ion of sputum seems high, such as with less-destroyed lungs,
nitial resistance to isoniazid and rifampicin, or resistance only
o isoniazid and rifampin, chemotherapy should be continued
or an additional 2 to 3 months. Should any significant changes
ccur clinically, chemotherapy should continue, whereas no
hange or a worsening in clinical, radiologic, or bacteriologic
ndings indicates surgery.
The mortality rate of 4.3 % in our group was slightly
igher than that of other reported groups. The Denver group
eported 6 (3.3%) of 180 patients,4 and such other groups 
he Japanese (30 patients),9 Turks (27 patients),2 and Kore-
ns (27 patients)16 reported no early mortality.
Fluoroquinolones, particularly moxifloxacin and gati-
oxacin, are believed to have the most activity in vitro
gainst Mycobacterium tuberculosis, followed by levo-
oxacin and ofloxacin.17-19 We used fluoroquinolones
ostly levofloxacin and gatifloxacin, in 66.6% of our pa- c
The Journal of Thoracicients (15/23), and 66.6% of the patients could be converted
o being sputum negative preoperatively. These results are
imilar to the results of Shiraishi and associates,9 who
eported a high conversion rate with levofloxacin used in a
ultidrug regimen.
Major complications after surgery for MDR-TB were
eported in between 15% and 40% of patients in the stud-
es.2-4,9 In our series, major complications occurred 
4.7% (8/23 patients). Half of our complications were as a
esult of prolonged air leaks that, except in 1 patient, were
anaged conservatively. The high incidence of air leakage
as a result of two factors.
First, it is a disease of the lung periphery, with extensive
ascular dense adhesions that affect the whole hemithorax
stage TB) and are not confined to the diseased lobe only. In
his group of patients, complete dissection of the lung was
andatory to ensure residual lung expansion. Subsequent
issections over unhealthy lower lobes were a source of air
eak.
Second, the residual lobe or lobes after resection were
lso pathologic, and lung expansion was not feasible, such
s in patients with bronchogenic carcinoma. These factors
re considerable in patients with tuberculosis. Although an
xtrapleural approach was adopted for many of our patients,
his was confined to the area of resected lobe. The main goal
as to avoid bleeding and opening cavities, but not air leak.
mong 4 patients who had air leak, 1 had an incomplete
ssure and the rest had air leak at the fissure site, an area
hat is usually difficult to control by staples or stitches.
Although use of biological glue has been reported with
ood results in other centers, our experience of treating
ostoperative air leak by infusions of 150 mL of autologous
lood, without the use of BioGlue surgical adhesive
CryoLife, Inc, Kennesaw, Ga) is extensive and yields an
lmost complete resolution. We used expectant treatment in
of 4 of our patients, and only the treatment for the patient
ith an incomplete fissure had to be revised. For this
articular patient, we used stitches over two pericardial
trips, reinforced with biological glue. One patient had air
eakage for 7 months, but she refused any interventions.
Similar to the techniques of other surgeons,2 we did no
se any muscle flaps to secure bronchial stumps because it
as hard to expect the presence of a large muscle bulk
wing to malnutrition problems. However, we were able to
se pleural flaps or pericardial fat pad to cover all bronchial
tumps after resection in patients treated by pneumonec-
omy and lobectomy. Except in our patient who died, we did
ot encounter any bronchopleural fistulas, serious space
roblems, or difficult empyemas that were not responding to
he first line of management, which was composed of ade-
uate drainage, antibiotics, and, in 1 patient, debridement.
e attribute this to our policy of avoiding extensive bron-hial dissection and manipulation.
and Cardiovascular Surgery ● Volume 134, Number 1 197
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G
TSStaple technique reduces time when compared with
and-sewn technique. However, apart from that, previous
eports have shown no major advantages of staple over
and-sewn technique. Our preferred sewing method was the
and-sewn technique, mainly because of lower cost.
For postoperative care we adopted an early extubation
olicy and did not use suction on the chest drains. Adequate
nalgesia, using epidural catheters, physiotherapy, incentive
pirometry, and early ambulation, played an important role
n achieving a higher success rate.
The majority of this series of patients has shown satis-
action on long-term follow-up. Those with hemoptysis or
onsiderable sputum production (large cavities, destroyed
ungs) were among those who enjoyed the most benefit. We
id not encounter any patient who reported having signifi-
ant dyspnea or exercise intolerance. To the contrary, most
f them had gained weight and had a general feeling of
ell-being.
Our success in this series is 91%, with 1 patient experi-
ncing relapse and another dying after the operation. The
uccess rate in other series has been reported to range
etween 83% and 93%.4,9
In summary, surgery remains an important adjunct tool
n the management of patients with MDR-TB. The success
f surgery depends on good cooperation between chest
hysicians and thoracic surgeons, patient compliance in
ompleting the postoperative drug regimen of 18 to 24
onths, surgical experience, adherence to preoperative and
ostoperative precautions, and careful follow-up.
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